EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
Chalela, Roberto (Hospital del Mar (Barcelona, Catalunya))
Bellosillo Paricio, Beatriz (Hospital del Mar (Barcelona, Catalunya))
Curull Serrano, Víctor (Universitat Autònoma de Barcelona. Departament de Medicina)
Longarón, Raquel (Hospital del Mar (Barcelona, Catalunya))
Pascual-Guardia, Sergi (Hospital del Mar (Barcelona, Catalunya))
Badenes-Bonet, Diana (Hospital del Mar (Barcelona, Catalunya))
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya))
Sánchez-Font, Albert (Universitat Autònoma de Barcelona. Departament de Medicina)
Pijuan, Lara (Hospital del Mar (Barcelona, Catalunya))
Gea Guiral, Joaquim (Hospital del Mar (Barcelona, Catalunya))

Date:	2019
Abstract:	Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutations observed in ADC can also be observed in the non-neoplastic lung tissue, as well as the short-term prognosis implications of this finding. Methods: Non-tumoral lung parenchyma specimens obtained during surgery from 47 patients with EGFR and/or KRAS abnormalities in their ADC tumors underwent similar genomic testing. Short-term outcomes were also recorded. Results: The same mutations were present in the tumor and the histologically normal tissue in 21. 3% of patients (SM group). Although local recurrences were similar in both groups, distant metastases were more frequent in the former (60 vs. 5. 4%, p < 0. 001). Moreover, SM patients showed lower time-to-progression (8. 5 vs. 11. 7 months, p < 0. 001) and disease-free survival (8. 5 vs. 11. 2 months, p < 0. 001). COX regression showed a higher risk of progression or death (DFS) in the SM group (HR 5. 94, p < 0. 01]. Similar results were observed when adjusting for potential confounding variables. Conclusions: These results confirm that genetic changes are present in the apparently normal lung in many ADC patients, and this finding has prognostic implications.
Note:	Altres ajuts: Fundació La Marató de TV3 (201305-30)
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Adenocarcinoma ; Mutations ; EGFR ; KRAS ; Prognosis
Published in:	Journal of clinical medicine, Vol. 8 (april 2019) , ISSN 2077-0383

DOI: 10.3390/jcm8040529
PMID: 30999636

12 p, 6.9 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles